Systems Medicine to Study Necrotizing Soft Tissue Infections (NSTIs).
Launched by KAROLINSKA INSTITUTET · Feb 11, 2013
Trial Information
Current as of May 07, 2025
Completed
Keywords
ClinConnect Summary
Patients will be prospectively recruited at 5 clinical centers (Rigshospitalet, Karolinska University Hospital, Blekinge University, Sahlgrenska University and University of Bergen). Clinical definition criteria for NSTI: NSTI is a clinical diagnosis. Initial signs are the occurrence of erythema, pain or tenderness beyond margins of erythema and swelling. Imaging and laboratory tests have little predictive value in the early stage. The gold standard modality for diagnosis of NSTI remains operative exploration. Operative findings that are consistent with NSTI include "dishwater or foul smell...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Necrotizing soft tissue infections
- Exclusion Criteria:
- • Patients under the age of 18 years
About Karolinska Institutet
Karolinska Institutet is a renowned medical university located in Sweden, recognized for its commitment to advancing healthcare through innovative research and education. As a leading sponsor of clinical trials, the institution focuses on translating scientific discoveries into effective treatments and therapies, emphasizing patient-centered approaches. With a strong emphasis on collaboration and interdisciplinary research, Karolinska Institutet plays a pivotal role in addressing global health challenges and improving patient outcomes, leveraging its extensive network of experts and state-of-the-art facilities to drive clinical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Copenhagen, , Denmark
Gothenburg, , Sweden
Stockholm, , Sweden
Bergen, , Norway
Gothenburg, , Sweden
Karlskrona, , Sweden
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials